<DOC>
	<DOCNO>NCT01386216</DOCNO>
	<brief_summary>The purpose study evaluate safety administration marrow-derived autologous hematopoietic stem cell ( HSC ) concentrate platelet-rich plasma ( PRP ) gel treatment Critical Limb Ischemia ( CLI ) .</brief_summary>
	<brief_title>Safety Study Bone Marrow Cell Concentrate Prepared Using Magellan System Treat Critical Limb Ischemia ( CLI )</brief_title>
	<detailed_description>Critical limb ischemia ( CLI ) continue important cause atherosclerotic morbidity mortality despite conventional therapy . Modulation angiogenesis promise alternative surgical revascularization . Trials isolate angiogenic growth factor therapy use recombinant protein gene transfer conduct , disappointing result unlikely single angiogenic factor solely even primarily responsible angiogenesis . Emerging stem cell therapy represent new approach modulation angiogenesis . Pluripotent hematopoietic stem cell ( HSC ) hold promise reproduce pro-angiogenic milieu ischemic limb rather upregulate single angiogenic factor . For CLI study , Magellan® System utilized preparation autologous cell concentrate point care . The bone marrow aspirate obtain patient concentrate cell concentration kit , deliver intramuscularly affect limb treatment impaired ischemic tissue order improve perfusion , reduce pain revascularize tissue patient inadequate tissue blood flow , prohibitive medical comorbidities , fail previous treatment revascularization prevention amputation .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Is able provide write informed consent prior study entry Is male female , 18 85 year age CLI rest pain , tissue loss , gangrene No option revascularization result one following : fail previous revascularization , recurrent instant restenosis graft occlusion . inadequate target vessel determine baseline CTA/angiogram time enrollment . prohibitive medical comorbidities high risk cardiovascular pulmonary disease would restrict operative procedure Final determination option revascularization make vascular surgeon associate clinical trial . ABI le 0.7 , ankle pressure &lt; 50 mmHg , toe pressure &lt; 30 mmHg . TcPO2 &lt; 40 mmHg SPP &lt; 35 mmHg Female subject must non childbearing potential ( define postmenopausal least 1 year surgically sterile [ bilateral tubal ligation , bilateral oophorectomy hysterectomy ] ) must use adequate contraception ( practice one follow method birth control ) : Total abstinence sexual intercourse ( minimum one complete menstrual cycle study entry ) , A partner physically unable impregnate subject ( e.g. , vasectomize ) Contraceptives ( oral , parenteral , transdermal ) 3 consecutive month prior patient 's cell concentrate administration , Intrauterine device ( IUD ) , Double barrier method ( condom , sponge , diaphragm , vaginal ring spermicidal jelly cream ) If female childbearing potential , subject must negative serum pregnancy test screen Confirmation ageappropriate cancer screen consistent American Cancer Society guideline Patients vascular lesion amenable percutaneous intervention surgical bypass indicate . Any contraindication stem cell plateletrich plasma therapy . Isolated aortoiliac stenosis occlusion without infrainguinal disease . Pregnancy Hemoglobin A1c &gt; 10 % day enrollment . Have active malignancy undergone treatment malignancy precede 5 year , exception successful treatment nonmelanoma skin cancer . Stage 4 great chronic kidney disease ( eGFR &lt; 30 ml/min , MDRD estimate ) Hemoglobin &lt; 10 g/dl . Thrombocytopenia &lt; 100,000 platelets/µL . Unwilling unable comply followup visit . Proliferative retinopathy determine baseline retinal exam . Is unable refrain nicotine , caffeine alcohol period begin 24 hour prior treatment visit Has receive investigational medication study trial participation within 30 day prior Treatment Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Critical limb ischemia</keyword>
	<keyword>Peripheral vascular disease</keyword>
	<keyword>platelet-rich plasma</keyword>
</DOC>